IQVIA MARKET PROGNOSIS
In these changing times, IQVIA is committed to deploying our resources and capabilities to providing continuous and timely insights into the healthcare industry and the impact of COVID-19.
The latest Market Prognosis country-level forecasts for 2022-2026 are now available, and include base case and downside perspectives on the potential impact of COVID-19* on pharmaceutical markets across the globe.
In the March 2022 release, discover:
North America:
- How the rebound in medicine demand and a return to pre-pandemic patient-physician behaviours will shape the US pharmaceutical market’s recovery
Europe:
- The implications of several measures introduced to accelerate access to new, innovative medicines in the UK
- How pharmaceutical market in Norway will shape up after the review of Nye Metoder system and National Insurance Scheme
- How Italy’s new drug price negotiation procedures and changes in pharmaceutical funding will impact market access for innovative drugs
- How Italy’s balancing act between cost containment and ensuring first-class patient care will impact market access to innovative treatments
- How the pandemic has boosted local R&D in Spain, from local production of CAR-T-cell therapies to developing a national COVID vaccine.
- Why the first therapeutic positioning report with an economic evaluation on Revlimid is a major step in Spain’s HTA landscape
- How new cost containment measures implemented in September 2021 will impact drug spending in the Turkish market
- What the impact of significant depreciation of the Turkish lira on pharmaceutical market growth rates in Turkey
Asia
- How changes to Indonesia’s national health insurance program and a restructuring of its funding mechanisms are expected to boost the program’s long-term sustainability
- How changes to Australia’s statutory pricing system under the next Strategic Agreement aim to free up additional funding for listing new medicines on the Pharmaceutical Benefit Scheme
- How will improvements in National Health Insurance reimbursement coverage and intensifying drug pricing reforms impact the future of the South Korean pharmaceutical market
- How Taiwan is leveraging horizon scanning and alternative reimbursement mechanisms for budgetary management of expensive innovative drugs
- How the pricing and reimbursement reforms in April 2022 will affect pharmaceutical market growth in Japan
- What the impact of the ongoing expansion of healthcare benefits under the Universal Coverage Scheme will be on Thailand’s pharmaceutical market
- How the evolution of the COVID-19 pandemic will impact the recovery of medical tourism in Thailand
- How the expansion of retail pharmacy chains and the use of digital health technology is expected to boost the Vietnamese pharma market
- The impact of the rapid expansion of volume-based procurement on structure and growth of the Chinese market over the medium term
LATAM:
- Why in a presidential election year in Brazil, politics could play an important influence on healthcare spending
- How public expenditure in healthcare and pharmaceuticals is expected to remain under check in Brazil in 2022 as budgets remain under pressure
- How inflation and the devalued Brazilian real will continue to be major factors impacting pharmaceutical market growth in 2022
- How increasing inflationary pressure and economic uncertainty are shaping Argentina’s pharmaceutical market, the government health policy and the industry outlook
- How the new government has improved Ecuador’s pharmaceutical market environment through pro-industry policies and via public-private partnerships
Want to know more about how Market Prognosis can help you access the sales forecasts that are necessary in order to anticipate which countries will offer opportunities and to establish annual targets?
Fill in the form and we’ll come back to you.
*The COVID-19 pandemic has posed unprecedented challenges in understanding pharmaceutical data trends and building meaningful forecasts. While Market Prognosis has leveraged IQVIA data assets as well as IQVIA internal expertise to compile the country forecasts, there is still great uncertainty about the evolution of the COVID-19 pandemic and its impact on pharmaceutical markets.
Copyright © 2024 IQVIA Holdings Inc. and its affiliates. All rights reserved. Privacy Statement
